Janux Therapeutics Stock Price on November 18, 2024
| JANX Stock | USD 56.14 0.61 1.07% |
If you're considering investing in Janux Stock, it is important to understand the factors that can impact its price. As of today, the current price of Janux Therapeutics stands at 56.14, as last reported on the 25th of December, with the highest price reaching 57.00 and the lowest price hitting 55.61 during the day. Janux Therapeutics appears to be not too volatile, given 3 months investment horizon. Janux Therapeutics holds Efficiency (Sharpe) Ratio of 0.0702, which attests that the entity had a 0.0702% return per unit of risk over the last 3 months. By evaluating Janux Therapeutics' technical indicators, you can evaluate if the expected return of 0.5% is justified by implied risk. Please utilize Janux Therapeutics' Downside Deviation of 3.3, market risk adjusted performance of 0.533, and Risk Adjusted Performance of 0.0506 to validate if our risk estimates are consistent with your expectations.
At this time, Janux Therapeutics' Common Stock Total Equity is fairly stable compared to the past year. Common Stock Shares Outstanding is likely to rise to about 46.2 M in 2024, whereas Total Stockholder Equity is likely to drop slightly above 221.9 M in 2024. . At this time, Janux Therapeutics' Price Book Value Ratio is fairly stable compared to the past year. Price To Book Ratio is likely to rise to 1.44 in 2024, whereas Price To Sales Ratio is likely to drop 55.51 in 2024. Janux Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
Janux |
Sharpe Ratio = 0.0702
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | JANX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.12 actual daily | 63 63% of assets are less volatile |
Expected Return
| 0.5 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Janux Therapeutics is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Janux Therapeutics by adding it to a well-diversified portfolio.
Price Book 5.0715 | Enterprise Value Ebitda (33.80) | Price Sales 254.9936 | Shares Float 38 M | Wall Street Target Price 91.6364 |
Related Headline
Fate Therapeutics Headline on 18th of November 2024
Fate Therapeutics Presents 6-Month Follow-up Data on First P... by finance.yahoo.com
27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies Patient Treated with Fludarabine-free Conditioning and Single-dose FT819 Favorable Safety Profile with No Grade 3 Adverse Events and No Events of CRS, ICANS, or GvHD Reconstituted B Cell Compartment Predominantly Consists of Nave, Non-class Switched B Cells with Deep Depletion of Aberrant B Cells an
Janux Therapeutics Valuation on November 18, 2024
It is possible to determine the worth of Janux Therapeutics on a given historical date. On November 18, 2024 Janux was worth 48.7 at the beginning of the trading date compared to the closed value of 48.12. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Janux Therapeutics stock. Still, in general, we apply an absolute valuation method to find Janux Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Janux Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Janux Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 50.41 | 51.09 | 48.34 | 48.76 | 699,104 | |
11/18/2024 | 48.70 | 49.14 | 47.04 | 48.12 | 530,206 |
| 47.75 | 49.74 | 47.50 | 49.01 | 632,330 |
| Backtest Janux Therapeutics | | | Janux Therapeutics History | | | Janux Therapeutics Valuation | Previous | Next |
Janux Therapeutics Trading Date Momentum on November 18, 2024
| On November 19 2024 Janux Therapeutics was traded for 49.01 at the closing time. The top price for the day was 49.74 and the lowest listed price was 47.50 . The trading volume for the day was 632.3 K. The trading history from November 19, 2024 was a factor to the next trading day price jump. The trading delta at closing time against the next closing price was 1.85% . The trading delta at closing time against the current closing price is 4.14% . |
Janux Therapeutics Fundamentals Correlations and Trends
By evaluating Janux Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Janux Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Janux financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Janux Therapeutics Stock history
Janux Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Janux is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Janux Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Janux Therapeutics stock prices may prove useful in developing a viable investing in Janux Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 44 M | 46.2 M | |
| Net Loss | -56.8 M | -53.9 M |
Janux Therapeutics Quarterly Net Working Capital |
|
Janux Therapeutics Stock Technical Analysis
Janux Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Janux Therapeutics Period Price Range
Low | December 25, 2024
| High |
0.00 | 0.00 |
Janux Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Janux Therapeutics December 25, 2024 Market Strength
Market strength indicators help investors to evaluate how Janux Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Janux Therapeutics shares will generate the highest return on investment. By undertsting and applying Janux Therapeutics stock market strength indicators, traders can identify Janux Therapeutics entry and exit signals to maximize returns
Janux Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Janux Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Janux Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Janux to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0506 | |||
| Jensen Alpha | 0.3315 | |||
| Total Risk Alpha | 0.0516 | |||
| Sortino Ratio | 0.0969 | |||
| Treynor Ratio | 0.523 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Janux Stock Analysis
When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.